Carole Ben-maimon - Net Worth and Insider Trading
Carole Ben-maimon Net Worth
The estimated net worth of Carole Ben-maimon is at least $2 Million dollars as of 2024-11-05. Carole Ben-maimon is the President and CEO of Larimar Therapeutics Inc and owns about 266,829 shares of Larimar Therapeutics Inc (LRMR) stock worth over $2 Million. Carole Ben-maimon is also the Director of Teligent Inc and owns about 1,600 shares of Teligent Inc (TLGTQ) stock worth over $0. Details can be seen in Carole Ben-maimon's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Carole Ben-maimon has not made any transactions after 2023-05-17 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Carole Ben-maimon
Carole Ben-maimon Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Carole Ben-maimon owns 2 companies in total, including Larimar Therapeutics Inc (LRMR) , and Teligent Inc (TLGTQ) .
Click here to see the complete history of Carole Ben-maimon’s form 4 insider trades.
Insider Ownership Summary of Carole Ben-maimon
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| LRMR | Larimar Therapeutics Inc | 2023-05-17 | director & President and CEO |
| TLGTQ | Teligent Inc | 2021-01-04 | director |
Carole Ben-maimon Latest Holdings Summary
Carole Ben-maimon currently owns a total of 2 stocks. Among these stocks, Carole Ben-maimon owns 266,829 shares of Larimar Therapeutics Inc (LRMR) as of May 17, 2023, with a value of $2 Million and a weighting of 100%. Carole Ben-maimon also owns 1,600 shares of Teligent Inc (TLGTQ) as of May 30, 2019, with a value of $0 and a weighting of 0%.
Latest Holdings of Carole Ben-maimon
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| LRMR | Larimar Therapeutics Inc | 2023-05-17 | 266,829 | 7.36 | 1,963,861 |
| TLGTQ | Teligent Inc | 2019-05-30 | 1,600 | 0.00 | 0 |
Holding Weightings of Carole Ben-maimon
Carole Ben-maimon Form 4 Trading Tracker
According to the SEC Form 4 filings, Carole Ben-maimon has made a total of 2 transactions in Larimar Therapeutics Inc (LRMR) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Larimar Therapeutics Inc is the acquisition of 5,000 shares on May 17, 2023, which cost Carole Ben-maimon around $18,550.
According to the SEC Form 4 filings, Carole Ben-maimon has made a total of 0 transactions in Teligent Inc (TLGTQ) over the past 5 years. The most-recent trade in Teligent Inc is the acquisition of 1,000 shares on May 30, 2019, which cost Carole Ben-maimon around $5,900.
Insider Trading History of Carole Ben-maimon
- 1
Carole Ben-maimon Trading Performance
GuruFocus tracks the stock performance after each of Carole Ben-maimon's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Carole Ben-maimon is 22.76%. GuruFocus also compares Carole Ben-maimon's trading performance to market benchmark return within the same time period. The performance of stocks bought by Carole Ben-maimon within 3 months outperforms 3 times out of 4 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Carole Ben-maimon's insider trading performs compared to the benchmark.
Performance of Carole Ben-maimon
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 0.46 | | | | | |
| Relative Return to S&P 500(%) | -1.3 | | | | | |
Carole Ben-maimon Ownership Network
Ownership Network List of Carole Ben-maimon
Ownership Network Relation of Carole Ben-maimon
Carole Ben-maimon Owned Company Details
What does Larimar Therapeutics Inc do?
Who are the key executives at Larimar Therapeutics Inc?
Carole Ben-maimon is the director & President and CEO of Larimar Therapeutics Inc. Other key executives at Larimar Therapeutics Inc include 10 percent owner & other: Possible Member of 10% Group James E Flynn , Chief Development Officer Gopi Shankar , and Chief Medical Officer Russell Clayton .
Larimar Therapeutics Inc (LRMR) Insider Trades Summary
Over the past 18 months, Carole Ben-maimon made 1 insider transaction in Larimar Therapeutics Inc (LRMR) with a net purchase of 5,000. Other recent insider transactions involving Larimar Therapeutics Inc (LRMR) include a net purchase of 4,290,617 shares made by James E Flynn , a net purchase of 57,208 shares made by Thomas Edward Hamilton , and a net purchase of 5,000 shares made by Michael Celano .
In summary, during the past 3 months, insiders sold 0 shares of Larimar Therapeutics Inc (LRMR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Larimar Therapeutics Inc (LRMR) were sold and 4,367,575 shares were bought by its insiders, resulting in a net purchase of 4,367,575 shares.
Larimar Therapeutics Inc (LRMR)'s detailed insider trading history can be found in Insider Trading Tracker table.
Larimar Therapeutics Inc Insider Transactions
Carole Ben-maimon Mailing Address
Above is the net worth, insider trading, and ownership report for Carole Ben-maimon. You might contact Carole Ben-maimon via mailing address: C/o Impax Laboratories, Inc., 30831 Huntwood Avenue, Hayward Ca 94544.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
